Pharming Group NV

Netherlands Country flag Netherlands
Sector: Biotechnology
Ticker: PHARM
ISIN: NL0010391025
Factsheet Factsheet

Market multiple valuation of Pharming Group NV ( PHARM | NLD)

The most common multiple used in the valuation of stocks is the P/Earnings NTM multiple (Price to Earnings). P/E relates the current share price with the market expectations in terms of Earnings Per Share. This multiple is used to compare a company's market value with its earnings. A company with a high P/Earnings NTM is considered to be overvalued; a company with a low P/Earnings NTM is considered to be undervalued.
The P/Earnings NTM ratio of Pharming Group NV is significantly lower than the median of its peer group: around 5.00. The company valuation of Pharming Group NV according to these metrics is way below the market valuation of its peer group.
The P/Earnings NTM ratio of Pharming Group NV is significantly higher than the average of its sector (Biotechnology): -0.95. The company valuation of Pharming Group NV according to these metrics is way above the market valuation of its sector.
The P/Earnings NTM ratio of Pharming Group NV is significantly lower than its historical 5-year average: 75.2. The (current) company valuation of Pharming Group NV is therefore way below its valuation average over the last five years.

Valuation
P/E Last P/E (e) 2025P/E NTM
Pharming Group NVFree trialFree trialFree trial
International PeersFree trialFree trialFree trial
Biotechnology-1.68-1.13-0.95
AEX 2518.8012.8513.77
Netherlands6.3310.039.81
More...
Beta (Ref: AEX 25)
Levered betaUnlevered beta
1-Year1.271.37
2-Year1.271.36
3-Year0.850.91
More...
Stock Perf excl. Dividends (in EUR)
PHARMAEX 25Rel. Perf.
Year-to-Date-20.4%-0.8%-19.7%
1-Week5.0%2.3%2.7%
1-Month-8.2%-4.8%-3.5%
1-Year-18.6%-0.2%-18.4%
3-Year-9.4%21.6%-31.0%
5-Year-42.0%72.7%-114.7%
More...
International Peers - Pharming Group NV
Company NameCtryMarket
Cap.
last (mUSD)
Pharming Group NVNLD-0.00
International Peers Median1.21
Pharvaris NVNLD859
BELLUS Health Inc.CANN/A
Bavarian Nordic A/SDNK-0.00
Biotest AGDEU-0.00
Lyell Immunopharma, Inc...USA130
GPRV Analysis
Created with Highcharts 4.1.70/102/104/106/108/1010/10
Pharming Group NV
Intl. Peers
U.S Patents No. 7,882,001 & 8,082,201
More...
Net Sales Chart
Created with Highcharts 4.1.7Millions USD201920202021202220232024 (e)2025 (e)2026 (e)2027 (e)0200400600
More...
Quotes Chart

1-Year Rebased Stock Chart

  • Pharming Group NV
  • AEX 25
Created with Highcharts 4.1.7Jan '25May '24Sep '24-40%-20%0%20%
More...

Did you know ?

On the Infront Analytics platform, there are two ways to identify the listed peers which most closely resemble a private firm:
- with Peer Tracker if you already know a listed peer.
Peer Tracker is a patented technology tool for building peer groups using industry classifications. The degree of similarity between two companies is calculated comparing their sector footprints and measured using comparability scores.
- with Market Screener if you have no listed peer in mind.
Market Screener is a dedicated interface for screening companies using multiple criteria, identifying peers, searching for comparable companies in a specific business sector.

About Market Multiples

Many methods can be used to value a company. In reality, business valuation is often a combination of these different approaches. One of the most widely used quantitative methods is the market multiples method. The market valuation is utilized generally as a primary market input, to provide an objective starting point for the valuation. Put simply, this method multiplies the sales or profits of a business by an industry averaged multiplier to calculate the Market Value of the business.
Current multiples include:
- Historical multiples based on standardized financials for the last completed fiscal period: Last, Last Twelve Months (LTM);
- Forward multiples based on consensus estimates for the current fiscal period and next ones: Next Twelve Months (NTM), FY0, FY1.
Current multiples based on per-share metrics (such as earnings per share or book value per share) are calculated using the last closing price, while current multiples based on company-level metrics (such as net sales, EBIT or EBITDA) are calculated using the current market cap or EV (Enterprise Value).